Abstract
Objective:The objective of this study was to investigate the clinical efficacy and safety of treating sepsis patients with Xuebijing injection(XBJI).Methods:We conducted a retrospective analysis of 418 patients who experienced severe infections and were treated with XBJI from June 2018 to June 2021.Propensity score matching was used to match the patient cases.The study population included 209 pairs of cases(418 individuals),and the analysis included data from before and after a 14-day course of treatment with carbapenem alone,or carbapenem with XBJI.Results:There were no significant differences in the 14-day mortality or length of hospital stay(P＞0.05)between the two groups.The combined treatment group had more patients with C-reactive protein that returned to normal levels(compared to baseline)than the non-combined treatment group(14.4％vs 8.1％;odds ratio[OR]:0.528;95％confidence interval[CI]:0.282-0.991;P=0.026).Similarly,the combined treatment group had higher procalcitonin attainment rate(55.0％vs 39.7％;OR:0.513;95％CI:0.346-0.759;P=0.001)than the non-combined treatment group.Further,more patients in the combined treat-ment group achieved normal creatinine levels than in the non-combined treatment group(64.1％vs 54.1％;OR:0.659;95％CI:0.445-0.975;P=0.037).Conclusion:The combination of XBJI with carbapenem did not reduce the 14-day mortality rate of patients with severe infection,but it was able to reduce the level of inflammatory factors in patients with sepsis,and had a protective effect on liver and kidney function.
国家科技期刊平台
NSTL
万方数据